Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Dendreon Stories

2011-01-05 06:30:00

SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2011 at 11:30 a.m. PT. The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor...

2010-12-15 15:02:39

The promise of vaccines targeted against various types of cancer has raised the hopes of patients and their families. The reality, however, is that these promising treatments are difficult to develop. One of the challenges is identifying a discrete cellular target to stop cancer growth without inactivating the immune system. Scientists at UNC Lineberger Comprehensive Cancer Center report a laboratory finding that has the potential to increase the effectiveness of therapeutic cancer vaccines....

2010-12-08 06:30:00

SEATTLE, Dec. 8, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the 2010 Deutsche Bank BioFEST conference in Boston on December 15, 2010 at 10:30 a.m. ET. The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor...

2010-12-03 07:00:00

SEATTLE, Dec. 3, 2010 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida and the Society of Urologic Oncology (SUO) Annual Meeting in Bethesda, Maryland. The following data presentations will take place at the ASH Annual Meeting on Saturday, December 4, 2010, at 5:30 p.m. ET: A poster titled,...

2010-11-18 13:51:00

Medicare Officials Will Consider the Panel's Endorsement When Deciding Whether Provenge Should Be Covered WASHINGTON, Nov. 18, 2010 /PRNewswire-USNewswire/ -- Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer. The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting was part of a national coverage analysis of Provenge, following...

2010-11-17 16:02:00

SEATTLE, Nov. 17, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) reviewed the impact of labeled and unlabeled use of PROVENGE® (sipuleucel-T) treatment on health outcomes of patients with advanced prostate cancer. This panel was convened as a part of the National Coverage Analysis (NCA) that was initiated by the Centers for Medicare and Medicaid Services...

2010-11-17 14:21:00

BALTIMORE, Nov. 17, 2010 /PRNewswire-USNewswire/ -- RetireSafe, a 400,000-supporter strong national advocacy group for older Americans, today urged the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to support the full reimbursement of costs related to the important new Provenge treatment procedure for prostate cancer patients. RetireSafe President Thair Phillips urged the Committee to "consider not only the many Americans suffering from prostate cancer, and their...

2010-11-16 06:30:00

WASHINGTON, Nov. 16, 2010 /PRNewswire/ -- Tomorrow is a landmark day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Provenge, a new prostate cancer treatment option, will be considered by the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC). MEDCAC was established to provide independent guidance and advice to the Centers for Medicare and Medicaid Services (CMS). MEDCAC is supposed to supplement CMS'...

2010-11-10 16:00:00

SEATTLE, Nov. 10, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that it has completed the submission of the post-approval supplement to the PROVENGE® (sipuleucel-T) Biologics License Application for the Morris Plains, New Jersey manufacturing facility. Dendreon is requesting licensure for an additional 36 workstations to manufacture PROVENGE. The standard U.S. Food and Drug Administration (FDA) review for a post-approval supplement to...

2010-11-10 08:00:00

WORCESTER, Mass., Nov. 10, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of...